IMA1 Antibody

What is the IMA1 antibody and what structures does it recognize?

The IMA1 antibody, also known as iMab, is a specialized antibody developed for the selective detection of i-Motif (iM) structures. i-Motifs are quadruplex nucleic acid conformations that form in cytosine-rich regions. Initially thought to form only in vitro due to their acidic pH dependence, the development of the iMab antibody has enabled detection of these structures in cells. The antibody selectively binds to both intramolecular i-Motifs (formed within a single DNA strand) and intermolecular i-Motifs (formed between multiple DNA strands) . Research has confirmed that iMab specifically recognizes the distinctive structural conformation of i-Motifs rather than merely binding to C-rich sequences, validating its use as a reliable detection tool for these important nucleic acid structures .

How do buffer conditions affect IMA1 antibody binding specificity?

The composition of buffers used during binding and washing steps strongly influences the selectivity of IMA1 antibody binding. Recent research has demonstrated that inappropriate buffer selection can lead to experimental artifacts that may obscure the true binding specificity of the antibody . To maintain optimal selectivity:

• pH conditions should be carefully controlled, as i-Motif formation is pH-dependent

• Salt concentrations should be optimized to maintain structural integrity

• Blocking agents should be selected that don't interfere with antibody-target interactions

The following table summarizes recommended buffer conditions for different experimental applications:

Optimizing these conditions is essential to avoid experimental artifacts and ensure the selective recognition of genuine i-Motif structures by the IMA1 antibody .

What controls should be included when using IMA1 antibody in experiments?

When designing experiments with the IMA1 antibody, appropriate controls are essential to validate results and exclude potential artifacts. Based on recent research, the following controls should be included:

• Negative sequence controls: C-rich sequences known not to form i-Motifs at experimental conditions

• Structure disruption controls: Treatment of samples with conditions that disrupt i-Motif structures (pH > 7.5)

• Competition assays: Pre-incubation of the antibody with known i-Motif structures

• Secondary antibody controls: Samples treated only with secondary detection antibodies

• DNA concentration gradients: Testing at multiple concentrations to avoid intermolecular i-Motif formation artifacts

Nuclear magnetic resonance (NMR) validation of control sequences is highly recommended, as several sequences previously thought not to form i-Motifs have been demonstrated to form intermolecular i-Motifs that are recognized by the IMA1 antibody . This unexpected finding emphasizes the importance of thoroughly characterizing control sequences before experimental use.

How can researchers optimize DNA concentrations to avoid artifacts in IMA1 antibody studies?

DNA concentration plays a critical role in avoiding experimental artifacts when working with the IMA1 antibody. At high DNA concentrations, C-rich sequences that would not normally form i-Motifs at physiological conditions might form intermolecular i-Motifs that are recognized by the antibody, potentially leading to false positive results . To avoid these artifacts:

• Perform preliminary titration experiments to determine optimal DNA concentrations

• Keep DNA concentrations below 5 μM for in vitro binding studies

• Use concentration gradients as controls to identify potential concentration-dependent effects

• Consider using locked nucleic acid (LNA) modifications to stabilize specific conformations

• Validate results with multiple detection methods beyond antibody binding

Additionally, researchers should be aware that buffer composition interacts with DNA concentration effects, with higher salt concentrations potentially promoting intermolecular structures at lower DNA concentrations . Therefore, a systematic approach to optimizing both parameters simultaneously is recommended.

How can NMR spectroscopy be used to validate IMA1 antibody binding specificity?

Nuclear magnetic resonance (NMR) spectroscopy provides a powerful method to validate the specificity of IMA1 antibody binding to genuine i-Motif structures. Recent research has employed NMR to demonstrate that several C-rich sequences, previously believed not to form i-Motifs, actually form intermolecular i-Motif structures that are selectively recognized by the IMA1 antibody . When implementing NMR validation:

• 1D 1H NMR spectra can identify the characteristic imino proton signals (15-16 ppm) that indicate cytosine-cytosine base pairing in i-Motif structures

• 2D NOESY experiments can confirm the spatial relationships between protons in the i-Motif structure

• pH titration studies using NMR can determine the pH-dependent formation and stability of putative i-Motif structures

• Concentration-dependent studies help distinguish between intramolecular and intermolecular i-Motif formation

The following table outlines key NMR parameters for i-Motif structure validation:

By combining NMR validation with IMA1 antibody binding studies, researchers can establish with high confidence whether a sequence forms genuine i-Motif structures that are specifically recognized by the antibody .

What is the relationship between IMA1 protein and iron acquisition pathways in response to immune challenges?

Research on IMA1 in plant systems has revealed complex interrelationships between iron acquisition pathways and immune responses. IMA1 (IRON MAN 1) plays a critical role in regulating iron uptake through the IRT1 (IRON-REGULATED TRANSPORTER 1) system, particularly under iron-deficient conditions . When plants encounter microbe-associated molecular patterns (MAMPs) like flg22:

• Flg22 treatment represses iron deficiency responses through downregulation of IMA1 in the outer tissue layers (ground tissue)

• The spatial regulation of IMA1 is crucial, with IMA1 levels in the epidermis and cortex being particularly important for IRT1 induction

• Constitutive expression of IMA1 in the epidermis and cortex renders plants insensitive to flg22-mediated repression of iron uptake

• IMA1 degradation occurs through the ubiquitin-dependent protein degradation pathway, which can be inhibited by MG132

The table below summarizes the tissue-specific effects of IMA1 expression on iron uptake responses:

These findings highlight the importance of spatial regulation of IMA1 in coordinating iron acquisition with immune responses, with IMA1 presence in the epidermis and cortex being necessary and sufficient for IRT1 induction .

How can researchers distinguish between intramolecular and intermolecular i-Motifs in IMA1 antibody binding studies?

Distinguishing between intramolecular and intermolecular i-Motifs is crucial for accurately interpreting IMA1 antibody binding results. Recent research has shown that the IMA1 antibody recognizes both types of structures, adding complexity to experimental design and data interpretation . To differentiate between these structures:

• Concentration dependence analysis: Intermolecular i-Motifs show strong concentration dependence, while intramolecular i-Motifs form even at very low concentrations

• Size exclusion chromatography: Can separate monomeric intramolecular i-Motifs from multimeric intermolecular structures

• Analytical ultracentrifugation: Provides accurate molecular weight determination to distinguish monomers from multimers

• Circular dichroism spectroscopy: Different spectral signatures for inter- vs intramolecular i-Motifs

• Native gel electrophoresis: Different migration patterns for monomeric vs multimeric structures

The following data table presents characteristic features that help distinguish between these i-Motif types:

Researchers should employ multiple methodologies in parallel to conclusively distinguish between these structures, as relying solely on IMA1 antibody binding patterns may be insufficient for definitive characterization .

What are the key methodological considerations when using IMA1 antibody for chromatin immunoprecipitation (ChIP) experiments?

Applying the IMA1 antibody in chromatin immunoprecipitation (ChIP) experiments requires special methodological considerations to maintain i-Motif structures and ensure specific binding. Based on current research practices:

• Crosslinking optimization: Standard formaldehyde crosslinking may disrupt i-Motif structures; gentler fixation protocols may be required

• pH maintenance: Buffers should be maintained at pH 6.0-6.5 throughout the procedure when possible

• Sonication parameters: Gentle sonication conditions help preserve i-Motif structures

• Buffer composition: The composition of IP and washing buffers strongly influences antibody binding selectivity

• Blocking optimization: BSA or other blocking agents need careful selection to prevent non-specific binding

The following protocol modifications are recommended for ChIP experiments with IMA1 antibody:

Additionally, researchers should include appropriate controls such as pH-shifted samples and competition with synthetic i-Motif structures to validate the specificity of chromatin interactions detected with the IMA1 antibody .

How does spatial regulation of IMA1 influence experimental design in plant immunology studies?

The spatial regulation of IMA1 in plant tissues presents unique considerations for experimental design in plant immunology studies. Research has shown that IMA1 exhibits tissue-specific expression patterns that are crucial for its function in linking iron homeostasis with immune responses . When designing experiments in this area:

• Tissue-specific expression systems: Use of promoters like pPGP4 (epidermis/cortex), pELTP (endodermis), and pLBD16 (pericycle) allows targeting IMA1 expression to specific cell types

• Visualization approaches: Fluorescent protein fusions (like mCitrine-IMA1) enable tracking of spatial protein distribution

• Quantification methods: Signal intensity profiles across root width provide quantitative measures of protein distribution

• Treatment timing: Differential responses occur depending on whether flg22 treatment is applied simultaneously with or after iron deficiency conditions

• Proteasome inhibitors: MG132 treatment helps determine the contribution of protein degradation to spatial regulation

The experimental approach should account for the finding that IMA1 needs to be locally expressed in the cortex and epidermis to induce IRT1, and that flg22 treatment leads to selective depletion of IMA1 in the ground tissue while preserving levels in the vasculature .

What are the best practices for storing and handling IMA1 antibody to maintain specificity?

Proper storage and handling of the IMA1 antibody is crucial for maintaining its specificity for i-Motif structures. Based on standard antibody practices and the specific requirements for maintaining recognition of pH-sensitive structures:

• Storage temperature: Store concentrated antibody at -20°C for long-term storage and at 4°C for working solutions

• Aliquoting: Prepare small single-use aliquots to avoid repeated freeze-thaw cycles

• Buffer composition: Store in a pH-stable buffer (pH 6.5-7.0) with appropriate preservatives

• Stabilizing additives: Consider adding 0.1% BSA or 50% glycerol to prevent adsorption to container surfaces

• Handling precautions: Minimize exposure to extreme temperatures or pH conditions that could alter antibody conformation

The following stability data provides guidance on expected antibody performance under different storage conditions:

Researchers should routinely validate antibody activity using positive control samples with known i-Motif structures before conducting critical experiments, especially with antibody preparations that have been stored for extended periods .

How can researchers troubleshoot non-specific binding issues with IMA1 antibody?

Non-specific binding can significantly impact the interpretation of results when using the IMA1 antibody. To troubleshoot these issues, researchers should implement a systematic approach:

• Optimize blocking conditions: Test different blocking agents (BSA, non-fat milk, casein) at varying concentrations

• Adjust antibody concentration: Perform titration experiments to determine optimal antibody dilutions

• Modify washing stringency: Increase the number of washes or add low concentrations of detergents

• Pre-absorb the antibody: Incubate with non-specific nucleic acids before use

• Evaluate buffer effects: Test different buffer compositions, as these strongly influence binding specificity

The following decision tree can guide troubleshooting of non-specific binding:

Recent research has emphasized that the composition of buffers used during binding and washing steps strongly influences selectivity, making buffer optimization a critical factor in reducing non-specific binding .

What approaches can be used to validate that IMA1 antibody binding reflects genuine i-Motif structures?

To ensure that IMA1 antibody binding truly reflects the presence of i-Motif structures rather than artifacts, a multi-modal validation approach is essential. Current research recommends:

• pH-dependent binding assays: Genuine i-Motifs show pH-dependent formation/unfolding that should be reflected in antibody binding

• Structure-specific chemical probing: Compounds like BQQ (bromoacetoethylpyridoquinoxaline) can be used as orthogonal i-Motif detection methods

• Circular dichroism spectroscopy: Characteristic spectral signatures at 285-295 nm confirm i-Motif structure

• Mutational analysis: Systematic mutation of cytosines should disrupt i-Motif formation and antibody binding

• Correlation with in silico predictions: Compare experimental results with computational predictions of i-Motif stability

Results from multiple validation approaches should be consolidated to provide strong evidence for genuine i-Motif structures, as demonstrated in the following validation matrix:

Recent research has demonstrated using nuclear magnetic resonance that several C-rich sequences not expected to form i-Motifs actually form intermolecular structures recognized by the IMA1 antibody, highlighting the importance of rigorous validation approaches .